# Study of KN046 With Chemotherapy in First Line Advanced NSCLC

> **NCT04054531** · PHASE2 · UNKNOWN · sponsor: **Jiangsu Alphamab Biopharmaceuticals Co., Ltd** · enrollment: 50 (estimated)

## Conditions studied

- Non-small Cell Lung Cancer

## Interventions

- **BIOLOGICAL:** KN046
- **DRUG:** Paclitaxel
- **DRUG:** Pemetrexed
- **DRUG:** Carboplatin

## Key facts

- **NCT ID:** NCT04054531
- **Lead sponsor:** Jiangsu Alphamab Biopharmaceuticals Co., Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-09-04
- **Primary completion:** 2021-03-01
- **Final completion:** 2021-06-01
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2019-09-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04054531

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04054531, "Study of KN046 With Chemotherapy in First Line Advanced NSCLC". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04054531. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*